Analysis of failed therapy evaluations in radioembolization of primary and secondary liver cancers.
Adult
Aged
Aged, 80 and over
Albumins
/ metabolism
Embolization, Therapeutic
/ methods
Female
Humans
Liver
/ metabolism
Liver Neoplasms
/ metabolism
Male
Middle Aged
Organotechnetium Compounds
/ administration & dosage
Radiopharmaceuticals
/ administration & dosage
Retrospective Studies
Technetium
/ administration & dosage
Tumor Burden
/ physiology
Young Adult
99mTc-macroaggregated albumin
Liver cancer
Pretreatment evaluation
Radioembolization
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
14
07
2020
accepted:
27
10
2020
pubmed:
7
11
2020
medline:
13
4
2021
entrez:
6
11
2020
Statut:
ppublish
Résumé
To analyze patients' characteristics and reasons for not performing planned transarterial radioembolization (TARE) in liver cancer after In this retrospective single-center cohort, all patients undergoing 436 patients [male = 248, female = 188, median age 62 (23-88) years] with A substantial number of patients are precluded from TARE following
Identifiants
pubmed: 33156407
doi: 10.1007/s00432-020-03443-z
pii: 10.1007/s00432-020-03443-z
pmc: PMC8021531
doi:
Substances chimiques
Albumins
0
Organotechnetium Compounds
0
Radiopharmaceuticals
0
Technetium-99
0
macro aggregates of albumin
70536-17-3
Technetium
7440-26-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1537-1545Références
Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C et al (2010) The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med 51(8):1206–1212. https://doi.org/10.2967/jnumed.109.074559
doi: 10.2967/jnumed.109.074559
pubmed: 20660379
Bailey JJ, Dewaraja Y, Hubers D, Srinivasa RN, Frey KA (2017) Biodistribution of 99mTc-MAA on SPECT/CT performed for 90Y radioembolization therapy planning: a pictorial review. Clin Transl Imaging 5(5):473–485. https://doi.org/10.1007/s40336-017-0245-8
doi: 10.1007/s40336-017-0245-8
pubmed: 29423383
pmcid: 5798624
Benson AB 3rd, Geschwind JF, Mulcahy MF, Rilling W, Siskin G, Wiseman G et al (2013) Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study. Eur J Cancer 49(15):3122–3130. https://doi.org/10.1016/j.ejca.2013.05.012
doi: 10.1016/j.ejca.2013.05.012
pubmed: 23777743
Bester L, Meteling B, Pocock N, Saxena A, Chua TC, Morris DL (2013) Radioembolisation with Yttrium-90 microspheres: an effective treatment modality for unresectable liver metastases. J Med Imaging Radiat Oncol 57(1):72–80. https://doi.org/10.1111/j.1754-9485.2012.02459.x
doi: 10.1111/j.1754-9485.2012.02459.x
pubmed: 23374558
Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J et al (2018) SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol 36(19):1913–1921. https://doi.org/10.1200/JCO.2017.76.0892
doi: 10.1200/JCO.2017.76.0892
pubmed: 29498924
Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL et al (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69(1):182–236. https://doi.org/10.1016/j.jhep.2018.03.019
doi: 10.1016/j.jhep.2018.03.019
Gibbs P, Heinemann V, Sharma NK, Taieb J, Ricke J, Peeters M et al (2018) Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy: combined analysis of two randomized controlled studies. Clin Colorectal Cancer 17(4):e617–e629. https://doi.org/10.1016/j.clcc.2018.06.001
doi: 10.1016/j.clcc.2018.06.001
pubmed: 30033117
Gormez A, Eldem FG, Salanci BV, Bozkurt MF, Ugur O, Peynircioglu B (2020) Utility of “dual phase” cone beam computed tomography during radioembolisation in patients with hepatocellular carcinoma: what is really changing in flow dynamics before and after (90)Y delivery? Pol J Radiol 85:e21–e28. https://doi.org/10.5114/pjr.2020.92915
doi: 10.5114/pjr.2020.92915
pubmed: 32180850
pmcid: 7064008
Hoffmann RT, Paprottka PM, Schon A, Bamberg F, Haug A, Durr EM et al (2012) Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol 35(1):105–116. https://doi.org/10.1007/s00270-011-0142-x
doi: 10.1007/s00270-011-0142-x
pubmed: 21431970
Ilhan H, Goritschan A, Paprottka P, Jakobs TF, Fendler WP, Todica A et al (2015) Predictive value of 99mTc-MAA SPECT for 90Y-labeled resin microsphere distribution in radioembolization of primary and secondary hepatic tumors. J Nucl Med 56(11):1654–1660. https://doi.org/10.2967/jnumed.115.162685
doi: 10.2967/jnumed.115.162685
pubmed: 26315830
Kallini JR, Gabr A, Hickey R, Kulik L, Desai K, Yang Y et al (2017) Indicators of lung shunt fraction determined by technetium-99 m macroaggregated albumin in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol 40(8):1213–1222. https://doi.org/10.1007/s00270-017-1619-z
doi: 10.1007/s00270-017-1619-z
pubmed: 28280976
Klompenhouwer EG, Dresen RC, Verslype C, Laenen A, De Hertogh G, Deroose CM et al (2017) Safety and efficacy of transarterial radioembolisation in patients with intermediate or advanced stage hepatocellular carcinoma refractory to chemoembolisation. Cardiovasc Intervent Radiol 40(12):1882–1890. https://doi.org/10.1007/s00270-017-1739-5
doi: 10.1007/s00270-017-1739-5
pubmed: 28685382
Kohler M, Harders F, Lohofer F, Paprottka PM, Schaarschmidt BM, Theysohn J et al (2019) Prognostic factors for overall survival in advanced intrahepatic cholangiocarcinoma treated with yttrium-90 radioembolization. J Clin Med. https://doi.org/10.3390/jcm9010056
doi: 10.3390/jcm9010056
pubmed: 31881761
pmcid: 7020033
Louie JD, Kothary N, Kuo WT, Hwang GL, Hofmann LV, Goris ML et al (2009) Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolization. JVIR 20(5):606–613. https://doi.org/10.1016/j.jvir.2009.01.021
doi: 10.1016/j.jvir.2009.01.021
pubmed: 19345589
Mahnken AH (2016) Current status of transarterial radioembolization. World J Radiol 8(5):449–459. https://doi.org/10.4329/wjr.v8.i5.449
doi: 10.4329/wjr.v8.i5.449
pubmed: 27247711
pmcid: 4882402
Maleux G, Izamis ML, Werbrouck C, Radaelli A, Prenen H, Van Cutsem E et al (2020) Characterization of liver metastases during catheter-directed liver interventions: a comparison between dual phase cone-beam computed tomography and conventional contrast-enhanced computed tomography. J Belg Soc Radiol 104(1):41. https://doi.org/10.5334/jbsr.2052
doi: 10.5334/jbsr.2052
pubmed: 32704616
pmcid: 7350946
Oberg K, Knigge U, Kwekkeboom D, Perren A (2012) Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):124–30. https://doi.org/10.1093/annonc/mds295
doi: 10.1093/annonc/mds295
Ricke J, Klumpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN et al (2019) Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol 71(6):1164–1174. https://doi.org/10.1016/j.jhep.2019.08.006
doi: 10.1016/j.jhep.2019.08.006
pubmed: 31421157
Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E et al (2015) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v8-30. https://doi.org/10.1093/annonc/mdv298
doi: 10.1093/annonc/mdv298
pubmed: 26314782
Smits MLJ, Dassen MG, Prince JF, Braat A, Beijst C, Bruijnen RCG et al (2019) The superior predictive value of (166)Ho-scout compared with (99m)Tc-macroaggregated albumin prior to (166)Ho-microspheres radioembolization in patients with liver metastases. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-019-04460-y
doi: 10.1007/s00259-019-04460-y
pubmed: 31399801
pmcid: 7075844
Theysohn JM, Ruhlmann M, Muller S, Dechene A, Best J, Haubold J et al (2015) Radioembolization with Y-90 glass microspheres: do we really need SPECT-CT to identify extrahepatic shunts? PLoS ONE 10(9):e0137587. https://doi.org/10.1371/journal.pone.0137587
doi: 10.1371/journal.pone.0137587
pubmed: 26335790
pmcid: 4559400
Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D (2016) Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5):v28–v37. https://doi.org/10.1093/annonc/mdw324
doi: 10.1093/annonc/mdw324
pubmed: 27664259
Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8):1386–1422. https://doi.org/10.1093/annonc/mdw235
doi: 10.1093/annonc/mdw235
pubmed: 27380959
van Hazel GA, Heinemann V, Sharma NK, Findlay MP, Ricke J, Peeters M et al (2016) SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 34(15):1723–1731. https://doi.org/10.1200/JCO.2015.66.1181
doi: 10.1200/JCO.2015.66.1181
pubmed: 26903575
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP et al (2017) Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 18(12):1624–1636. https://doi.org/10.1016/S1470-2045(17)30683-6
doi: 10.1016/S1470-2045(17)30683-6
pubmed: 29107679
Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J et al (2017) First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol 18(9):1159–1171. https://doi.org/10.1016/S1470-2045(17)30457-6
doi: 10.1016/S1470-2045(17)30457-6
pubmed: 28781171
pmcid: 5593813
Wondergem M, Smits ML, Elschot M, de Jong HW, Verkooijen HM, van den Bosch MA et al (2013) 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization. J Nucl Med 54(8):1294–1301. https://doi.org/10.2967/jnumed.112.117614
doi: 10.2967/jnumed.112.117614
pubmed: 23749996